维生素K2对血液透析患者血管钙化影响的随机对照试验
单中心随机对照试验纳入178例维持性血液透析患者,随机分为维生素K2组(甲萘醌-7 360 μg每周3次)与对照组,随访18个月。主要终点冠状动脉钙化评分两组无统计学差异(RMD 0.85,95%CI 0.55-1.31),维生素K2补充降低了dp-ucMGP水平,但未减少血管钙化进展。
要点
- 维生素K2 360 μg每周3次补充18个月未显著降低冠状动脉钙化评分。
- 主动脉瓣钙化、cfPWV、AIx等次要终点两组均无显著差异。
- 维生素K2组dp-ucMGP水平显著降低,但MACE与死亡复合终点无差异。
核心结论
- 在本研究剂量和疗程下,维生素K2补充未显示出减少血液透析患者血管钙化进展的获益。
研究设计与样本
- 单中心随机对照试验,纳入维持性血液透析患者178例,随机分为维生素K2组(甲萘醌-7 360 μg每周3次)与对照组,随访18个月,完成随访138例。
主要发现
- 18个月末冠状动脉钙化评分两组无统计学差异(RMD 0.85,95%CI 0.55-1.31)。
- 主动脉瓣钙化两组无显著差异(RMD 0.82,95%CI 0.34-1.98)。
- cfPWV两组无显著差异(AMD 0.55,95%CI -0.50至1.60)。
- AIx两组无显著差异(AMD 0.13,95%CI -3.55至3.80)。
- 维生素K2组dp-ucMGP水平降低(AMD -86,95%CI -854至-117)。
关键数值与推荐
- 维生素K2组干预为甲萘醌-7 360 μg每周3次。
- 主要终点为研究结束时冠状动脉钙化评分。
- 次要终点包括主动脉瓣钙化、cfPWV、AIx、dp-ucMGP、MACE和血管通路事件。
临床怎么用
- 在本研究剂量和疗程下,维生素K2补充未显示减少血液透析患者血管钙化进展的获益。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Vitamin K deficiency among patients on hemodialysis (HD) affects the function of matrix GLA protein (MGP), a potent vitamin K-dependent inhibitor of vascular calcification (VC). METHODS: We conducted a single-center randomized controlled trial (RCT) on maintenance HD patients to examine if vitamin K2 supplementation can reduce progression of coronary artery calcification (CAC) over an 18-month study period. Patients were randomized to vitamin K2 group receiving menaquinone-7360 μg 3 times/wk or control group. The primary outcome was CAC scores at the end of the study period. The secondary outcomes were aortic valve calcification (AVC), carotid-femoral pulse wave velocity (cfPWV), aortic augmentation index (AIx), dephosphorylated undercarboxylated MGP (dp-ucMGP) levels, major adverse cardiac events (MACE), and vascular access events. RESULTS: Of the 178 patients randomized, follow-up was completed for 138 patients. The CAC scores between the 2 groups were not statistically different at the end of 18 months (relative mean difference [RMD] 0.85, 95% CI 0.55-1.31). The secondary outcomes did not differ significantly in AVC (RMD 0.82, 95% CI 0.34-1.98), cfPWV (absolute mean difference [AMD] 0.55, 95% CI -0.50 to 1.60), and AIx (AMD 0.13, 95% CI -3.55 to 3.80). Supplementation with vitamin K2 did reduce dp-ucMGP levels (AMD -86, 95% CI -854 to -117). The composite outcome of MACE and mortality was not statistically different between the 2 groups (Hazard ratio = 0.98, 95% CI 0.50-1.94). CONCLUSION: Our study did not demonstrate a beneficial effect of vitamin K2 in reducing progression of VC in this population at the studied dose and duration.
引用
- Haroon S, Davenport A, Ling LH, et al. Randomized Controlled Clinical Trial of the Effect of Treatment with Vitamin K2 on Vascular Calcification in Hemodialysis Patients (Trevasc-HDK). Kidney Int Rep. 2023. PMID: 37705910. doi:10.1016/j.ekir.2023.06.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。